Chronic obstructive pulmonary disease and emphysema are known to be associated with air pollution and smoking habit [
36]. COPD and emphysema reduce the respiratory capability of the subject and induce lung injury which in several situations are life threatening [
37]. Currently several drugs such as inhaled bronchodilators, inhaled corticosteroids, phosphodiesterase-4 inhibitors and mucolytics are used as symptomatic therapy and blockage of inflammation [
38]-[
40]. Other drugs such as macrolides have been also used for control of COPD exacerbations by exploiting their anti-inflammatory properties [
41]. It has been observed that during COPD exacerbation the circulating endothelial stem cells are not decreased, however; their population is abnormally high, probably during an effort for tissue repair and inflammation control [
42],[
43]. Increased levels of vascular endothelial growth factor (VEGF) have been associated with increased levels of circulating endothelial stem cells [
43]. It has been previously observed that mesenchymal stem cells protect cigarette smoke lung injury, by up-regulating vascular endothelial growth factor receptor 2 and tumor growth factor β-1, and down-regulating inflammatory response, cell apoptosis and excessive protease expression [
27]. In laboratory model experiments, mesenchymal stem cells have been co-cultured with scaffolds. Producing functional parts of the respiratory system, provided evidence that these cells might be used for tissue repair in the airways [
44]. The same observation has been made for other diseases of the respiratory system such pulmonary fibrosis, cystic fibrosis and pulmonary hypertension [
45]. In vivo imaging of these cells has been previously accomplished during airway regeneration in mice [
30]. It has been also shown that bone marrow cells could repair cigarette induced emphysema [
28],[
46]. The same observation was made for stem cells derived from the adipose tissue [
47]. However; there is an ongoing investigation regarding another stem cell population such as the bronchioalveolar stem cells, and how this population affects the initiation of a respiratory disease and whether it can reverse it [
48]. Other researches use basal stem cells and investigate their role in epithelial homeostasis and remodeling [
49]. Activation of satellite cells in the intercostals muscles has been also proposed as an additional method of assisting the respiratory function of COPD patients [
50]. Based on previously presented data, clinical studies have been started, evaluating the potential tissue repair ability of stem cells by administering them in patients with copd [
28],[
29],[
31]. Early results indicate that the stem cell administration is safe and that the respiratory function can be improved. Currently this treatment lacks of pathological evidence of whether it can truly regenerate alveoli units, or whether the improvement of the respiratory function is due to the anti-inflammatory property. It has been previously proposed that mesenchymal stem cells have the ability to regenerate tissue [
51]. Even if these cells had unlimited capabilities, the main problem of an in vivo tissue engineering effort is to make a cell population create new healthy and functioning alveoli as in our case, or repair damaged ones. There are several possible approaches. One could create a scaffold with an extracellular matrix guiding stem cells to create the desired structure or one could bioengineer stem cell with the genetic information to create alveoli. Possibly a disease by disease case should be investigated. In our experiment we provide a novel model of emphysema. We found no pathological evidence that under these conditions, stem cells would create new alveoli tissue or any other structure of the respiratory system. However; image analysis proved that the stem cells assisted in down-regulating the inflammation of the trigger factor (DDMC non-viral vector). Lipopolysaccharides have been also recently used to induce emphysema [
52]. The anti-inflammatory effect has been previously observed in other studies [
27]. Major limitations of our study were firstly the lack of inflammatory marker evaluation however; tissue damage is observed to be inversely associated with the administration of Human Umbilical Cord Mesenchymal Cells (HUCMCs) population. Secondly we did not evaluate the survival of the groups, however; our objective was to present solid data (pathological) whether stem cells regenerate any kind of tissue formation within the lung parenchyma when a lung injury trigger factor exists. Moreover; we did not evaluate the population of stem cells deposited per mm
2 of alveoli. It was impossible to know exactly the population of the stem cells instilled in the lungs and hoe of them were deposited in the alveoli since the mice in several occasions exhaled the stem cell compound due to cough. Additionally, less damage to the alveoli was observed next to vessels (<10μm) probably, because as previously observed these cells are attract by vascular endothelial growth factors [
53].
In our current work we investigated the protective effect of adult Human Umbilical Cord Mesenchymal Cells (HUCMCs) in a gene therapy induced emphysema model. We observed that any dosage from ≥50.000cells has a protective effect. The observation that we find most interesting is that around the vessels of the lung parenchyma in an area of no more than 10μm the emphysema lesions were significantly reduced. Our conclusion based on pathological findings is that vessels transport the regenerative cells and are diffused through the vascular wall to the regional tissue and that a kind of scaffold is necessary for the stem cells to regenerate lung parenchyma constructions.